ERBB2 and breast carcinoma: These lymphocytes are believed to exhibit anti-tumoral effects in HER2-positive breast cancer through immune-mediated tumour-host interactions and antibody-dependent cellular cytotoxicity (ADCC), as observed in numerous other cancer types [9, 10].